Summit slips on ivonescimab's apparent interim miss in sign of investor frustration
Summit因ivonescimab疑似中期未达标而受挫，投资者不满情绪升温

Summit Therapeutics’ stock price $SMMT tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3 trial for its cancer drug ivonescimab.
周四盘后，Summit Therapeutics（股票代码：SMMT）股价大跌近20%，此前其癌症药物ivonescimab在一项三期试验的部分环节似乎未达到统计学指标。